decisionhealth Newsletters, Answer Books - 2009 Issue 3 (March)
Anti-Kickback Advisory Opinion Summaries / 2004 OIG Advisory Opinions / Opinion 04-01 - Supplier May Waive Copayments For Clinical Trial Participants
Subscribe or sign in to view the full article.
Article Overview
This premium article reviews a 2004 HHS Office of Inspector General advisory opinion involving a medical supply company, an NIH clinical trial, and the proposed waiver of copayments for study participants. It is relevant to compliance, fraud-and-abuse, and healthcare reimbursement audiences who want a high-level understanding of the agency’s position and the general factors discussed in the opinion.
Why This Topic Matters
The article matters because it addresses how an OIG advisory opinion evaluates a supplier’s cost-sharing waiver policy in the context of a federally controlled clinical trial. Readers concerned with compliance, anti-kickback issues, and trial-related reimbursement policy can use it to assess whether the full opinion is relevant to their work.
What You Will Learn
- The compliance issues raised by waiving patient cost-sharing in a clinical trial setting
- How an OIG advisory opinion frames the relationship between supplier practices and beneficiary influence concerns
- The general role of NIH oversight in the clinical trial discussed
- Why the article is relevant to anti-kickback and reimbursement compliance review
Who Should Read This
- Compliance officers
- Medical coders
- Billing professionals
- Healthcare attorneys
- Risk management staff
- Clinical research administrators
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com